Cadila Healthcare Ltd (Zydus Cadila) has forayed into a pact with World Health Organisation (WHO) to explore collaboration in the development of a cocktail for the treatment of rabies, via the use of monoclonal antibodies (MAbs), the next-generation biologicals.
The WHO will be giving monoclonal antibodies capable of neutralising rabies virus and genetic sequences thereof, for valuation at the Zydus Research Centre, the research arm of the pharmaceutical major here.
The development and commercialisation of the cocktail will, among others, be designed to get its wide availability to the public, comprising in particular its availability to the public sector of developing countries at a preferential price. Zydus Cadila, said the new therapy holds much assure as it will address a critical need and enable the company to offer a complete range of rabies therapeutics at an affordable cost. Zydus Cadila manufactures and markets rabies vaccines known as VaxiRab and LyssavacN.
The WHO will be giving monoclonal antibodies capable of neutralising rabies virus and genetic sequences thereof, for valuation at the Zydus Research Centre, the research arm of the pharmaceutical major here.
The development and commercialisation of the cocktail will, among others, be designed to get its wide availability to the public, comprising in particular its availability to the public sector of developing countries at a preferential price. Zydus Cadila, said the new therapy holds much assure as it will address a critical need and enable the company to offer a complete range of rabies therapeutics at an affordable cost. Zydus Cadila manufactures and markets rabies vaccines known as VaxiRab and LyssavacN.
No comments:
Post a Comment